FY2025 EPS Estimate for ProQR Therapeutics Lifted by Analyst

ProQR Therapeutics (NASDAQ:PRQR) – Analysts at Chardan Capital increased their FY2025 EPS estimates for ProQR Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will post earnings of ($0.33) per share for the year, up from their previous forecast of ($0.34). Chardan Capital has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

PRQR has been the topic of several other reports. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Oppenheimer assumed coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, Citigroup raised ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 target price for the company in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

ProQR Therapeutics Trading Down 2.1 %

ProQR Therapeutics stock opened at $1.40 on Thursday. ProQR Therapeutics has a 1-year low of $1.40 and a 1-year high of $4.62. The firm’s fifty day simple moving average is $2.08 and its 200-day simple moving average is $2.59. The company has a market capitalization of $147.30 million, a P/E ratio of -4.38 and a beta of 0.24.

Hedge Funds Weigh In On ProQR Therapeutics

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the last quarter. Bank of America Corp DE boosted its position in shares of ProQR Therapeutics by 11.8% in the fourth quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 8,621 shares during the period. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter worth $30,000. Squarepoint Ops LLC increased its position in ProQR Therapeutics by 16.3% during the fourth quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 11,623 shares during the period. Finally, Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).